Ascendis Pharma A/S – Financial and Clinical Highlights (November 2025)

1. Earnings Outlook for Q3 2025

  • Analyst consensus: 15 analysts now expect a narrower loss per share of –0.244 EUR for the quarter ended 30 September 2025, compared with a loss of –1.890 USD per share in the same period last year.
  • Revenue expectations: The average forecast for the quarter is 213.2 million EUR, a substantial increase from the 63.5 million USD reported in Q3 2024.
  • Year‑to‑date guidance: For the fiscal year ending 2025, analysts project a loss per share of –2.315 EUR, down from –7.060 USD per share in the prior year, while revenue is expected to reach 713 million EUR versus 393.4 million USD previously.

These revisions follow the company’s announcement that it will report earnings on 12 November 2025, with the expectation that the loss margin will tighten relative to the prior year.

2. Market Context – Hypoparathyroidism

  • Growth projection: The global market for hypoparathyroidism treatment is projected to expand to USD 1.15 billion by 2035, rising from USD 785.7 million in 2025 at a CAGR of 3.9 %.
  • Drivers: Increased prevalence, post‑surgical cases, and the development of recombinant parathyroid hormone (rPTH) therapies, notably TransCon PTH, are cited as key growth factors.
  • Relevance to Ascendis: The company’s flagship product, TransCon PTH (palopegteriparatide), is a once‑weekly rPTH therapy designed for patients with hypoparathyroidism.

3. Clinical Evidence – TransCon PTH

  • Pooled analysis: A 3‑year pooled analysis from the Phase 2 PaTH Forward and Phase 3 PaTHway trials demonstrated sustained, clinically meaningful improvements in renal function for adults with hypoparathyroidism.
  • Key findings: The improvement in estimated glomerular filtration rate (eGFR) was consistent across both trials and maintained through year 3 of treatment.
  • Presentation: Results were presented at Kidney Week 2025 by Dr. Elvira Gosmanova, a nephrologist at Albany Medical College and Albany VAMC.

4. Company Profile

  • Sector and industry: Biotechnology, Health Care.
  • Primary exchange: Nasdaq.
  • Recent share price: USD 201.16 (close on 10 November 2025).
  • Market cap: Approximately USD 11.98 billion.
  • Price‑earnings ratio: –39.45, reflecting the company’s current operating losses.
  • Product portfolio: Includes therapies for growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes, with a current focus on rare endocrine disorders such as hypoparathyroidism.

5. Conclusion

Ascendis Pharma A/S is positioned to deliver a tighter quarterly loss and stronger revenue figures for Q3 2025, supported by positive market growth expectations for hypoparathyroidism and robust clinical data for its lead product, TransCon PTH. The company’s financial guidance and clinical milestones suggest a trajectory of improvement, while the broader market environment remains favorable for its therapeutic area.